EUVIMEDEUVIMED entdecken
Crossref

Protective Effects of Herbacetin in Experimental Colitis: Targeting NF‐κB and NLRP3 Pathways

Yousra Bseiso, Badriyah S Alotaibi, Alaa A A Aljabali iD, Omar Gammoh iD, Mohammad E Rabeh, Ahmad M Rabi, Esam Qnais, Abdelrahim Alqudah iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Yousra Bseiso und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, NF-kappa B, Flavonoids, Colitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at the Hashemite University, Zarqa, Jordan (Grant number: 31….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) resulting from a dysregulation of immune responses. Herbacetin, a flavonoid of natural origin, has been found to exert an anti‐inflammatory action, though its actions in experimental colitis are unknown. Colitis was induced in BALB/c mice with 2,4,6‐trinitrobenzenesulfonic acid (TNBS). Mice were administered with herbacetin (25, 50, 100 mg/kg) or sulfasalazine (100 mg/kg) orally for 7 days. The disease activity index (DAI), colon length, weight/length ratio, histopathology, MPO and NO contents, and inflammatory gene expression (NF‐κB, iNOS, COX‐2, NLRP3, IL‐1β, IL‐18) were evaluated. TNBS induced marked weight loss and increased DAI ( p < 0.01 vs. NC). Body weight ( p < 0.01) and DAI ( p < 0.01) were significantly ameliorated by herbacetin, especially at 50 and 100 mg/kg. TNBS significantly reduced the colon length ( p < 0.001) and increased the weight/length ratio ( p < 0.001), which were significantly counteracted by herbacetin ( p < 0.01–0.001). TNBS mice presented with mucosal injury and inflammatory infiltration were demonstrated by histopathology ( p < 0.001) and a dose‐dependent healing effect was observed in herbacetin‐treated mice. TNBS mice had higher levels of MPO and NO ( p < 0.001), which were significantly attenuated by herbacetin ( p < 0.01–0.001). Herbacetin decreased the mRNA expression levels of NF‐κB, iNOS, COX‐2, NLRP3, IL‐1β, and IL‐18 in a dose‐dependent ( p < 0.05–0.001). Herbacetin exerts a protective effect in colitis by suppressing neutrophil infiltration, oxidative stress, and NF‐κB–NLRP3‐mediated inflammation, highlighting the potential of herbacetin‐based treatment for UC and related inflammatory bowel diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinNF-kappa BFlavonoidsColitisAnti-Inflammatory AgentsColitis, UlcerativeAnimalsMice, Inbred BALB CMiceMaleTrinitrobenzenesulfonic AcidSignal TransductionDisease Models, AnimalColon

Stichwörter der Autor:innen

NF‐κBNLRP3 inflammasomeTNBS‐induced colitisherbacetinulcerative colitis

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinNF-kappa BNlrp3 protein, mouseTrinitrobenzenesulfonic AcidFlavonoidsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pahrmacy, Jerash University, Jerash, Jordan.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan.

ORCID-Profile: Alaa A A Aljabali, Omar Gammoh, Abdelrahim Alqudah

Förderung

  • The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at the Hashemite University, Zarqa, Jordan (Grant number: 31…

Zitieren

APA

Bseiso, Y., Alotaibi, B. S., Aljabali, A. A. A., Gammoh, O., Rabeh, M. E., Rabi, A. M., Qnais, E., & Alqudah, A. (2026). Protective Effects of Herbacetin in Experimental Colitis: Targeting NF‐κB and NLRP3 Pathways. Drug Development Research. https://doi.org/10.1002/ddr.70195

Vancouver

Bseiso Y, Alotaibi BS, Aljabali AAA, Gammoh O, Rabeh ME, Rabi AM, et al. Protective Effects of Herbacetin in Experimental Colitis: Targeting NF‐κB and NLRP3 Pathways. Drug Development Research. 2026. doi:10.1002/ddr.70195

BibTeX
@article{Bseiso2026,
  author = {Bseiso, Yousra and Alotaibi, Badriyah S and Aljabali, Alaa A A and Gammoh, Omar and Rabeh, Mohammad E and Rabi, Ahmad M and Qnais, Esam and Alqudah, Abdelrahim},
  title = {Protective Effects of Herbacetin in Experimental Colitis: Targeting NF‐κB and NLRP3 Pathways},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70195}
}
Kostenlos starten →